Sanjida Ahmed Srishti
Overview
Explore the profile of Sanjida Ahmed Srishti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
11
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srishti S, Pinky P, Taylor R, Guess J, Karlik N, Janjic J
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771467
Skin inflammation represents a hallmark of many skin conditions, from psoriasis to eczema. Here, we present a novel microemulsion formulation for delivering a low dose of potent immunosuppressant, tacrolimus, to...
2.
Ahmed S, Krishnan A, Karim O, Shafique K, Naher N, Srishti S, et al.
Lancet Glob Health
. 2024 Aug;
12(10):e1706-e1719.
PMID: 39178879
In the south Asian region, delivering non-communicable disease (NCD) prevention and control services through existing primary health-care (PHC) facilities is urgently required yet currently challenging. As the first point of...
3.
Vieira M, Andia T, Karim O, Srishti S, Pineda S, Ruiz A, et al.
J Pharm Policy Pract
. 2023 Nov;
16(1):155.
PMID: 38012700
Background: There is growing interest in pharmaceutical innovation in low- and middle-income countries (LMICs), but information on existing activities, capacities, and outcomes is scarce. We mapped available data at the...
4.
Rahman M, Azad S, Uddin M, Farzana M, Sharmeen I, Kabbo K, et al.
Mol Divers
. 2023 Oct;
28(5):3045-3066.
PMID: 37902899
The research aimed to establish a multidrug-resistant Klebsiella pneumoniae-induced genetic model for mastitis considering the alternative mechanisms of the DjlA-mediated CbpA protein regulation. The Whole Genome Sequencing of the newly...
5.
Morshed A, Azad S, Mia M, Uddin M, Ema T, Yeasin R, et al.
Mol Divers
. 2022 Nov;
27(6):2651-2672.
PMID: 36445532
The HER2-positive patients occupy ~ 30% of the total breast cancer patients globally where no prevalent drugs are available to mitigate the frequent metastasis clinically except lapatinib and neratinib. This...